Custom Search


Sunday 01 October 2006

Ziprasidone-induced cognitive enhancement in schizophrenia: Specificity or pseudospecificity?

By: Malhotra AK, Burdick KE, Razi K, Bates JA, Sanders M, Kane JM.

Schizophr Res 2006 Oct;87(1-3):181-4

OBJECTIVE: Ziprasidone may improve cognition in schizophrenia; however, this could be related to clinical symptom improvement, reflecting "pseudospecificity". We tested the hypothesis that ziprasidone improves cognition in the absence of clinical improvement. METHODS: We conducted a 12-week, open-label study of ziprasidone in 10 schizophrenia patients who met non-response criteria (<20% reduction in BPRS scores over 12 weeks). We conducted comprehensive cognitive testing and assessed change from baseline to end of study. RESULTS: We detected significant improvement on three measures of episodic memory (p<0.01) in these clinically non-responsive patients. Trend-level improvements were noted on tests involving processing speed and executive function. CONCLUSIONS: These data suggest that ziprasidone has cognitive benefits unrelated to an influence on other disease parameters.

Use of this site is subject to the following terms of use